Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Multiple claims are not supported by the provided label text (especially brand withdrawal status, mechanism details, and exact iPLEDGE monitoring elements). Some items that are supported (indication scope, retinoid class, iPLEDGE enrollment/contraception concepts, psychiatric and birth-defect warnings, and common dryness effects) are outweighed by substantial unsupported/incorrect claims.
Category Scores
Accurate Statements
Isotretinoin belongs to a class of drugs called retinoids.
CLINICAL PHARMACOLOGY: "Isotretinoin is a retinoid".
Accutane may cause depression, psycho sis and, rarely, suicidal ideation, suicide attempts, suicide, and aggressive and/or violent behaviors.
WARNINGS: "Accutane may cause depression, psychosis and, rarely, suicidal ideation, suicide attempts, suicide, and aggressive and/or violent behaviors."
Accutane can cause depression.
WARNINGS (Psychiatric Disorders) and Medication Guide: "Accutane may cause: depression".
Accutane can cause suicidal thoughts.
WARNINGS (Psychiatric Disorders) and Medication Guide: "suicidal ideation" / "suicidal thoughts".
Accutane is indicated for the treatment of severe recalcitrant nodular acne and should be reserved for patients unresponsive to conventional therapy including systemic antibiotics.
INDICATIONS AND USAGE: "Accutane is indicated for the treatment of severe recalcitrant nodular acne" and "should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics."
Patients must be enrolled in the iPLEDGE program.
PRECAUTIONS: "Accutane must only be prescribed by prescribers who are enrolled and activated with the iPLEDGE REMS." and "must only be dispensed to patients who are enrolled".
Common side effects of Accutane include dryness of the skin.
MEDICATION GUIDE: "The common, less serious side effects of Accutane are dry skin, chapped lips, dry eyes, and dry nose..."
Common side effects of Accutane include dryness of the lips.
MEDICATION GUIDE: "dry skin, chapped lips, dry eyes, and dry nose..."
Common side effects of Accutane include dryness of the eyes.
MEDICATION GUIDE: "dry skin, chapped lips, dry eyes, and dry nose..."
Unsupported Statements
Accutane is a brand name for isotretinoin.
The provided label text does not explicitly state that Accutane is a brand name for isotretinoin (though it contains medication guide labeling for Accutane (isotretinoin capsules) and "Active Ingredient: isotretinoin USP"; an explicit 'brand name for' phrasing is not present in the supplied excerpt).
Isotretinoin is primarily used to treat severe, recalcitrant nodular acne.
The provided label shows an indication for severe recalcitrant nodular acne but does not use the word 'primarily' or otherwise support the claim framing 'primarily used' from the excerpt.
Isotretinoin works by reducing the size of sebaceous glands in the skin.
CLINICAL PHARMACOLOGY states: "inhibits sebaceous gland function and keratinization" and the exact mechanism is unknown; it does not state 'reducing the size' of sebaceous glands.
Isotretinoin works by reducing oil production of sebaceous glands in the skin.
Label supports inhibiting sebaceous gland function, but the excerpt does not use 'reducing oil production' wording; mechanism details beyond 'inhibits sebaceous gland function and keratinization' are not provided.
Isotretinoin decreases the amount of sebum produced.
The excerpt does not explicitly state sebum quantity decreases; it states inhibition of sebaceous gland function.
Isotretinoin reduces inflammation.
The excerpt does not state an anti-inflammatory mechanism; it states inhibition of sebaceous gland function and keratinization.
Isotretinoin prevents clogging of pores.
The excerpt states inhibition of keratinization, but does not explicitly state prevention of pore clogging.
These actions collectively help clear severe acne.
The label excerpt does not connect those listed mechanistic actions to 'collectively help clear' in that specific causal framing.
These actions collectively help prevent new breakouts.
No such claim about preventing new breakouts appears in the provided label excerpt.
The iPLEDGE program involves regular pregnancy tests.
The label excerpt supports pregnancy testing requirements (e.g., monthly negative CLIA-certified tests), but the claim 'regular pregnancy tests' is overly general and not stated with that exact characterization in the excerpt.
The iPLEDGE program requires commitment to using highly effective contraception.
The label excerpt requires two forms of effective contraception simultaneously (at least one primary), but it does not use the phrase 'highly effective contraception'.
Accutane was voluntarily withdrawn from the U.S. market by its manufacturer, Hoffmann-La Roche, in 2009.
No market-withdrawal history appears in the provided label excerpt.
The active ingredient isotretinoin is still available in the U.S.
No availability statement appears in the provided label excerpt.
The active ingredient isotretinoin is available in other countries under different brand names or as a generic medication.
No cross-country availability/generic branding information appears in the provided label excerpt.
Regulatory bodies continue to monitor the safety of isotretinoin.
The provided excerpt references reporting to FDA MedWatch and an iPLEDGE Pregnancy Registry, but it does not explicitly claim that regulatory bodies 'continue to monitor' safety.
Contradictions
Low
AI Statement
Accutane is prescribed under strict safety monitoring programs.
Label Reference
PRECAUTIONS and Medication Guide support iPLEDGE REMS requirements, but 'strict safety monitoring programs' is not stated in those exact terms. No direct contradiction with the provided text.
Important Omissions
For pregnancy prevention, the label specifies specific iPLEDGE requirements including not being pregnant, use of two forms of effective contraception simultaneously for at least one month prior to initiation, during treatment, and for one month after discontinuation, and negative CLIA-certified pregnancy testing at required intervals. The AI claims only broadly about iPLEDGE and contraception and omits several core required elements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported or overly general mechanistic and product-history claims (including withdrawal/availability statements) could mislead readers, while partial iPLEDGE/contraception descriptions omit specific required elements. Psychiatric and pregnancy-related warnings were directionally aligned with the label excerpt.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Not Aligned
Primary Issue
Several claims are not supported by the provided label excerpt (mechanism-of-action details, product withdrawal/availability, and some iPLEDGE descriptions).
Suggested Improvement
Restrict statements to what the label excerpt explicitly supports (e.g., 'inhibits sebaceous gland function and keratinization' rather than specific oil/sebum/anti-inflammatory/pore-clogging mechanisms; omit withdrawal/availability statements not present in the label; describe iPLEDGE pregnancy testing and contraception using the label’s specific requirements for two forms of effective contraception and CLIA-certified pregnancy tests).